Treatment

KEYTRUDA 25 mg/mL concentrate for solution for infusion., LIBTAYO 350 mg concentrate for solution for infusion. clinical trials

1 indexed studies · 0 currently recruiting

AuthorisedTherapeutic exploratory (Phase II)
METAREM / META-1 - METAREM : Adaptive Master Trial for Advanced Cancers with Rapid Evaluation of Molecular & Immune Status for Stratified Immunotherapies in Oncology / META-1 : Anti-PD1 monotherapy in 1L advanced NSCLC patients with PDL1 TPS > 50% and PTI=0
This study looks at new treatments for advanced cancers, including a specific lung cancer called NSCLC. It tests two medicines, Keytruda and Libtayo, to see if they can stop cancer from growing and improve patients' lives.
For: METAREM:Patients with advanced cancer, as defined as unresectable locally advanced malignancies or metastatic cancers (including leukemias and lymphomas).
France